Stock comparison
Mettler-Toledo International
Telix Pharmaceuticals Limited
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
TLX
Telix Pharmaceuticals Limited
Market cap
$3.21B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | MTD | TLX | Winner |
|---|---|---|---|
| Warren Buffett | 69B | 31F | MTD |
| Benjamin Graham | 65B | 49D | MTD |
| Philip Fisher | 63C | 50C | MTD |
| Peter Lynch | 66B | 29F | MTD |
| Joel Greenblatt | 68B | 0F | MTD |
| Charlie Munger | 74B | 44D | MTD |
| Terry Smith | 70B | 38D | MTD |
Side-by-side metrics
| Metric | MTD | TLX |
|---|---|---|
| Market cap | $22.29B | $3.21B |
| P/E (TTM) | 25.3x | - |
| EV/EBIT | 21.6x | 211.6x |
| ROIC (TTM) | 36.09% | 1.77% |
| Gross margin | 57.79% | 50.76% |
| Net margin | 21.4% | -0.89% |
| Revenue CAGR 5y | 2.01% | 2.55% |
| EPS CAGR 5y | 6.12% | - |
| Debt / Equity | - | 1.3x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
MTD leads on
- Net margin21.4%vs -0.89%+104%
- Debt / Equity-vs 1.3x+102%
- ROIC (TTM)36.09%vs 1.77%+95%
- EV/EBIT21.6xvs 211.6x+90%
TLX leads on
- P/E (TTM)-vs 25.3x+105%
- Revenue CAGR 5y2.55%vs 2.01%+99%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.